Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$57.32

-1.895 (-3.20%)

, SPNE

SeaSpine

$12.00

-0.58 (-4.61%)

06:27
12/12/19
12/12
06:27
12/12/19
06:27

SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo

Wells Fargo analyst Lawrence Biegelsen double-downgraded Glaukos (GKOS) and SeaSpine (SPNE) to Underweight from Overweight as part of his broader Medical Technology industry research note. The analyst expects the medical device sector to be part of the "politics of healthcare" storm heading into next year's elections given the focus on drug pricing and increasing access to healthcare, even though he sees the broader risks as "manageable" for another year with "medtech tax" likely to be suspended. Biegelsen also cuts his rating on Merit Medical (MMSI) to Underweight from Equal Weight, but offers a positive view on Medtronic (MDT), citing its accelerating growth story trading at a discount relative to peer valuation and sees Teleflex (TFX) as "among the best positioned" in his coverage with UroLift as its key growth accelerator.

GKOS

Glaukos

$57.32

-1.895 (-3.20%)

SPNE

SeaSpine

$12.00

-0.58 (-4.61%)

MMSI

Merit Medical

$29.99

0.69 (2.35%)

MDT

Medtronic

$111.67

0.62 (0.56%)

TFX

Teleflex

$354.93

1.18 (0.33%)

  • 18

    Feb

GKOS Glaukos
$57.32

-1.895 (-3.20%)

09/12/19
PIPR
09/12/19
NO CHANGE
Target $80
PIPR
Overweight
Piper says buy Glaukos as Avedro deal has 'homerun potential'
Piper Jaffray analyst Matt O'Brien believes Glaukos' (GKOS) acquisition of Avedro (AVDR) has "homerun potential." In the near-term, Avedro should quadruple Glaukos' total addressable market to $4B and accelerate its revenue growth in 2020, "plugging the gap ahead of iDose," O'Brien tells investors in a research note following a deep dive analysis. Longer term, Glaukos is "putting together the pieces of what could become an ophthalmology powerhouse," addressing a potential opportunity of greater than $40B, adds the analyst. He "strongly" encourages investors to take a look at the Glaukos story today as he sees at least $80 per share of value in just the base businesses alone. O'Brien reiterates an Overweight rating on the shares with an $80 price target.
10/24/19
SPHN
10/24/19
NO CHANGE
Target $95
SPHN
Overweight
Glaukos could benefit from Allergan's 'unfortunate' XEN hold, says Stephens
Stephens analyst Chris Cooley noted Allergan's (AGN) initiation earlier this week of a voluntary recall of affected lots of XEN 45 and precautionary temporary product hold. Though XEN usage is reserved for moderate to severe cases of POAG, the "unfortunate" temporary hold may create additional opportunities for Glaukos (GKOS) to train and convert glaucoma specialists to iStent inject, contends Cooley. The analyst, who said he remains confident in Glaukos' ability to achieve low-teens percentage MIGS growth in calendar 2020, keeps an Overweight rating on Glaukos shares.
12/12/19
WELS
12/12/19
DOWNGRADE
Target $58
WELS
Underweight
Glaukos downgraded to Underweight from Overweight at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen double downgraded Glaukos to Underweight from Overweight with a price target of $58.
09/30/19
BOFA
09/30/19
DOWNGRADE
Target $67
BOFA
Underperform
Glaukos downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Bob Hopkins double downgraded Glaukos (GKOS) to Underperform from Buy and lowered his price target for the shares to $67 from $75. The analyst remains bullish on the company's long term prospects and sees no issues with its Q3 and Q4 results, but he prefers other names in the space given the potential distraction associated with the integration of Avedro. Hopkins also lowered his price target for ShockWave Medical (SWAV) to $40 from $64 and for Intersect ENT (XENT) to $22 from $39.
SPNE SeaSpine
$12.00

-0.58 (-4.61%)

05/02/19
PIPR
05/02/19
NO CHANGE
Target $20
PIPR
Overweight
Piper Jaffray 'strongly' encourages buying SeaSpine after Q1 results
Piper Jaffray analyst Matt O'Brien "strongly" encourages investors to buy shares of SeaSpine Holdings following the company's Q1 results. "We simply cannot find a valid excuse for investors to stay away from the name," O'Brien writes in a post-earnings research note. He expects more earnings beats as SeaSpine's new products enter broader market launches. The analyst keeps an Overweight rating on the shares with a $20 price target.
12/12/19
WELS
12/12/19
DOWNGRADE
Target $13
WELS
Underweight
SeaSpine downgraded to Underweight from Overweight at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen double downgraded SeaSpine Holdings to Underweight from Overweight with a $13 price target.
10/30/19
PIPR
10/30/19
NO CHANGE
Target $20
PIPR
Overweight
Piper Jaffray sees more upside surprises for SeaSpine
SeaSpine last night announced Q3 results that once again beat on the top-line, with management raising guidance for the full year as well, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The analyst believes "more is to come" given SeaSpine's suite of new products that are entering broader market launches to go along with more and more instrument sets. He sees "too many good things here to ignore" and keeps an Overweight rating on the shares with a $20 price target.
07/12/19
PIPR
07/12/19
NO CHANGE
Target $20
PIPR
Overweight
Piper 'strongly' encourages purchase of SeaSpine shares
Piper Jaffray analyst Matt O'Brien "strongly" encourages purchase of SeaSpine Holdings shares after the company announced the full commercial launch of Regatta, a lateral interbody device featuring the company's proprietary NanoMetalene technology. . This launch, the full launch of Mariner expected in Q3, as well as several other hardware and biologics expected later this year should position SeaSpine to continue its string of quarterly beats, O'Brien tells investors in a research note. He reiterates an Overweight rating on the name with a $20 price target.
MMSI Merit Medical
$29.99

0.69 (2.35%)

10/31/19
PIPR
10/31/19
NO CHANGE
Target $30
PIPR
Overweight
Merit Medical price target lowered to $30 from $40 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target for Merit Medical Systems to $30 from $40 saying the company reported disappointing Q3 results and lowered guidance for the full year. Management also removed their 2020 guidance, "leaving investors uncertain about the growth outlook for the business," O'Brien tells investors in a research note. He expects a "harsh reaction" in the stock today keeps an Overweight rating on Merit Medical as he believes the "franchise can turn around."
12/12/19
WELS
12/12/19
DOWNGRADE
Target $26
WELS
Underweight
Merit Medical downgraded to Underweight from Equal Weight at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen downgraded Merit Medical Systems to Underweight from Equal Weight with a $26 price target.
09/24/19
09/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Disney (DIS) was initiated with an Outperform at Wells Fargo, while Netflix (NFLX) was initiated with a Market Perform, and CBS (CBS), Viacom (VIAB, VIA), and Fox Corp. (FOXA) were initiated with Underperform ratings. 2. Merit Medical (MMSI) initiated with an Outperform at Oppenheimer. 3. Global Payments (GPN) reinstated with a Buy at Goldman Sachs. 4. 10x Genomics (TXG) initiated with an Outperform at Evercore ISI. 5. Corcept Therapeutics (CORT) and Strongbridge Biopharma (SBBP) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/19
BRRR
10/31/19
NO CHANGE
Target $31
BRRR
Outperform
Merit Medical price target lowered to $31 from $59 at Barrington
Barrington analyst Michael Petusky lowered his price target for Merit Medical Systems to $31 from $59 saying the company's profitability in Q3 fell well short and its guidance was reduced significantly. Merit's "somewhat disappointing" revenue growth rate was less to blame for the quarter's profitability miss than the company's lack of discipline regarding operating expenses, Petusky tells investors in a post-earnings research note. He keeps an Outperform rating on the shares.
MDT Medtronic
$111.67

0.62 (0.56%)

12/10/19
MSCO
12/10/19
NO CHANGE
Target $42
MSCO
Overweight
Morgan Stanley raises Axonics estimates after 'bullish' survey of urologists
Morgan Stanley analyst David Lewis said his survey of 82 urologists and one urogynecologist in the U.S. was bullish for sacral neuromodulation system, or SNM, market growth, leading him to raise his market growth assumptions. His survey also shows that physicians plan to shift relatively quickly toward Axonics (AXNX), though its share may contract after Medtronic's (MDT) next-gen Interstim Micro introduction in mid-2020, added Lewis. The analyst, who updated his assumptions to reflect Axonics reaching 16% U.S. market share by mid-2020 and 21% share in 2021, both of which are up from his prior estimates, keeps an Overweight rating and $42 price target on Axonics shares.
12/03/19
GUGG
12/03/19
NO CHANGE
Target $8
GUGG
Buy
Strategic element of ViewRay news 'more profound' than capital, says Guggenheim
Guggenheim analyst Chris Pasquale said he believes ViewRay's (VRAY) plans to issue $75M in new equity "should go a long way toward mitigating" investor concerns about the company's cash burn and balance sheet. However, as important as this improved liquidity is, he sees the strategic implications of collaborations with both Elekta (EKTAY) and Medtronic (MDT) as "even more profound," telling investors that the participation of two large, strategic partners in the equity raise is a significant endorsement of ViewRay's technology. Pasquale reiterates his Buy rating on ViewRay shares, which are up $1.10, or 32% to $4.50 in pre-market trading.
12/03/19
MZHO
12/03/19
NO CHANGE
Target $9
MZHO
Buy
Mizuho views ViewRay deals, capital raise favorably
ViewRay (VRAY) last night announced the signature of non-binding memoranda of understanding with Elekta AB (EKTAY) and Medtronic (MDT) as well as a common stock offering for $75M, Mizuho analyst Difei Yang tells investors in a research note. Elekta and Medtronic are taking stakes in ViewRay as part of the stock offering, the analyst points out. Yang views these announcements favorably and believes they are further validation of ViewRay's MRIdian technology in addition to removing its financing overhang. The analyst reiterates a Buy rating on the shares with a $9 price target.
11/25/19
ARGS
11/25/19
NO CHANGE
Target $135
ARGS
Buy
Medtronic price target raised to $135 from $120 at Argus
Argus analyst David Toung raised his price target on Medtronic to $135 and kept his Buy rating after its Q2 earnings beat that was driven by growth upside in Restorative Therapies Group and the Minimally Invasive Therapies Group businesses. The analyst also cites the company's "solid performance in emerging markets" and the strong sales of its diabetes products overseas, raising his FY20 and FY21 EPS views by 3c and 2c to $5.63 and $6.12 respectively.
TFX Teleflex
$354.93

1.18 (0.33%)

10/31/19
PIPR
10/31/19
NO CHANGE
Target $400
PIPR
Overweight
Urolift driving majority of Teleflex earnings beat, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $400 price target on Teleflex after its Q3 earnings beat and a narrowed higher guidance for FY19. The analyst notes that Urolift drove much of the beat and management reflected positively on expectations for 2020 with several new products contributing, including Urolift 2 and Manta. O'Brien adds that Teleflex remains "among the cleanest large cap growth stories" in his coverage universe.
08/02/19
NEED
08/02/19
NO CHANGE
Target $403
NEED
Buy
Teleflex price target raised to $403 from $325 at Needham
Needham analyst Mike Matson raised his price target on Teleflex to $403 and kept his Buy rating, saying its Q2 earnings beat shows the company caught "lightning in a bottle" with its UroLift system. The analyst points to the 9.6% organic revenue growth in the quarter in spite of the tougher comps and sees the 80bps decline in operating margins driven by the "incremental selling expense investments". Matson contends that the core business of TeleFlex is durable, and its Manta, and Percuvance could be sources of potential upside heading into 2020.
08/05/19
JMPS
08/05/19
NO CHANGE
Target $395
JMPS
Outperform
Teleflex price target raised to $395 from $325 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Teleflex to $395 and kept his Outperform rating after its Q2 earnings beat, saying the quarter was "particularly impressive" as organic growth accelerated from Q1 into a double-digit range. The analyst believes that the stock should continue to appreciate given the management's efforts to boost profitability through "restructuring initiatives and manufacturing excellence programs."
08/05/19
JMPS
08/05/19
NO CHANGE
Target $395
JMPS
Outperform
Teleflex price target raised to $395 from $325 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Teleflex to $395 and kept his Outperform rating after its Q2 earnings beat, saying the quarter was "particularly impressive" as organic growth accelerated from Q1 into a double-digit range. The analyst believes that the stock should continue to appreciate given the management's efforts to boost profitability through "restructuring initiatives and manufacturing excellence programs."

TODAY'S FREE FLY STORIES

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/17/20
01/17
16:17
01/17/20
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/17/20
01/17
16:16
01/17/20
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
01/17/20
01/17
16:15
01/17/20
16:15
General news
Treasury Market Summary »

Treasury Market Summary:…

LGC

Legacy Acquisition Corp

$10.33

(0.00%)

16:08
01/17/20
01/17
16:08
01/17/20
16:08
Hot Stocks
Legacy Acquisition Corp extends date to consummate proposed business combination »

Legacy Acquisition Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$0.33

-0.015 (-4.41%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Syndicate
Breaking Syndicate news story on Genius Brands »

Genius Brands files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$90.21

1.28 (1.44%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Periodicals
Best Buy board opens investigation into CEO's personal conduct, WSJ says »

The board of Best Buy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.